TARO-GABAPENTIN CAPSULE
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
16-12-2020
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
GABAPENTIN
Fáanlegur frá:
TARO PHARMACEUTICALS INC
ATC númer:
N02BF01
INN (Alþjóðlegt nafn):
GABAPENTIN
Skammtar:
100MG
Lyfjaform:
CAPSULE
Samsetning:
GABAPENTIN 100MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
MISCELLANEOUS ANTICONVULSANTS
Vörulýsing:
Active ingredient group (AIG) number: 0125929001; AHFS:
Leyfisstaða:
CANCELLED PRE MARKET
Leyfisdagur:
2023-11-08
Vara einkenni
_ _
_Taro-Gabapentin Product Monograph _
_Page 1 of 30_
PRODUCT MONOGRAPH
Pr
TARO-GABAPENTIN
Gabapentin
Capsules 100 mg, 300 mg and 400 mg
Antiepileptic Agent
Taro Pharmaceuticals Inc.
130 East Drive
Brampton, Ontario
L6T 1C1
Date of Revision: December
16, 2020
Submission Control No: 245306
_ _
_Taro-Gabapentin Product Monograph _
_Page 2 of 30_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
15
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 20
PART II: SCIENTIFIC INFORMATION
..............................................................................
21
PHARMACEUTICAL INFORMATION
.........................................................................
21
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
........
Lestu allt skjalið
